The estimated Net Worth of Cynthia W. Hu is at least $248 Tausend dollars as of 14 January 2019. Cynthia Hu owns over 15,000 units of CASI Pharmaceuticals Inc stock worth over $247,527 and over the last 10 years Cynthia sold CASI stock worth over $0.
Cynthia has made over 2 trades of the CASI Pharmaceuticals Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Cynthia exercised 15,000 units of CASI stock worth $26,400 on 14 January 2019.
The largest trade Cynthia's ever made was buying 16,800 units of CASI Pharmaceuticals Inc stock on 19 January 2016 worth over $12,096. On average, Cynthia trades about 2,650 units every 91 days since 2014. As of 14 January 2019 Cynthia still owns at least 32,785 units of CASI Pharmaceuticals Inc stock.
You can see the complete history of Cynthia Hu stock trades at the bottom of the page.
Cynthia's mailing address filed with the SEC is CASI PHARMACEUTICALS, INC., 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE, MD, 20850.
Over the last 12 years, insiders at CASI Pharmaceuticals Inc have traded over $0 worth of CASI Pharmaceuticals Inc stock and bought 30,834,178 units worth $51,898,666 . The most active insiders traders include Wei Wu He, Rajesh C Md Shrotriya und Pharmaceuticals Inc Spectru.... On average, CASI Pharmaceuticals Inc executives and independent directors trade stock every 91 days with the average trade being worth of $6,141,555. The most recent stock trade was executed by James Huang on 6 September 2022, trading 55,573 units of CASI stock currently worth $229,516.
CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. The Company intends to execute its plan to become a leader by launching medicines in the Greater China market leveraging the Company’s China-based regulatory and commercial competencies and its global drug development expertise. The Company’s operations in China are conducted through its wholly-owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd. (“CASI China”), which is located in Beijing, China. The Company has built a commercial team of over 70 hematology and oncology sales and marketing specialists based in China.
CASI Pharmaceuticals Inc executives and other stock owners filed with the SEC include: